MedTrace Logo

Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)

NCT01856855 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-01-12

Study results available
· View outcomes & findings →

Summary

This study will investigate the safety, tolerability, and effectiveness of giving a higher dose to the part of the prostate which contains the cancer while giving a standard radiation dose to the entire prostate. The investigators have hypothesized that this treatment technique will effectively control the prostate cancer while minimizing the side effects.

Conditions

  • Prostate Cancer
  • Prostate Adenocarcinoma
  • Radiation Toxicity
  • Sexual Dysfunction

Interventions

RADIATION

Stereotactic Body Radiation Therapy with Integrated Boost

SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions

Sponsors & Collaborators

  • John Fiveash, MD

    lead OTHER

Principal Investigators

  • John B Fiveash, MD · University of Alabama at Birmingham Radiation Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01856855 on ClinicalTrials.gov